The Official Journal of AONN+ - Journal of Oncology Navigation & Survivorship

Category VIII: Survivorship and End of Life
This year, there are no accepted abstracts within this research category.
Developing and Sustaining Patient Navigation Programs in Low- and Middle-Income Countries
The American Cancer Society aims to implement navigation programs abroad through the BEACON Initiative.
AONN+ Annual Conference Monograph: A Study of Key Sessions
Meg Barbor, MPH
At the recent AONN+ Annual Conference, experts in oncology navigation convened virtually with conference attendees to offer their insights in furthering the efficacy of navigation. This monograph will review the proceedings from 4 key sessions covering the timely topics of telehealth, mental health and the oncology patient, prehabilitation and rehabilitation, and value-based oncology care.
Using Telehealth to Expand the Reach of Palliative Care
Telehealth is a valuable tool for delivering early palliative care to patients with cancer, especially for particularly vulnerable populations such as those with advanced disease.
Understanding Paget’s Disease Accompanied by Invasive Breast Cancer
Cathy J. F. Cole, NP, MPH, CHES, FNCBC
An essential primer on this rare form of breast cancer and the implications for the Navigator.
Therapeutic Cancer Vaccines: The Next Frontier
Faith A. Mutale, MSN, CRNP, Cecile Miller, MSN, CRNP
The authors provide a brief background and an overview of cancer vaccine therapy, current research, clinical application, and current challenges.
Addressing Barriers to Fertility Preservation for Cancer Patients: The Role of Oncofertility Patient Navigation
Caroline S. Dorfman, PhD, Juliann M. Stalls, PhD, Coleman Mills, MA, Shannon Voelkel, BS, Mallori Thompson, MA, Kelly S. Acharya, MD, Karen C. Baker, MD, Lars M. Wagner, MD, Nolan Miller, MHA, Amy Boswell, MSN, Cheyenne Corbett, PhD
Overview of Current Imaging Modalities in Prostate Cancer
Neal Shore, MD, FACS
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY^® (piflufolastat F 18).
The Countdown to the AONN+ Annual Conference!
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG